Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Mats L. Brune, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Donna E. Hogge, MD, John Catalano, MD, Elisabeth Wallhult, RN, Bo I. Nilsson, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Stephane Allard, MD, Edward A. Stadtmauer, MD, Kristoffer Hellstrand, MD

Blood (2007) 110 (11): 1846.

https://doi.org/10.1182/blood.V110.11.1846.1846

Published: 2007

Journal Articles

Low Predictive Value of Functional Imaging with 18 FDG-PET or Gallium Scanning in Relapsed or Refractory Hodgkin Lymphoma Prior to Autologous Stem Cell Transplantation.

Stefan Peinert, MD, Rosemary Hoyt, MD, Jeff Szer, MD, Andrew Roberts, MD, Andrew Grigg, MD, H. Miles Prince, MD, Luigi Rigacci, MD, John F. Seymour, MD, David S. Ritchie, MD

Blood (2007) 110 (11): 5127.

https://doi.org/10.1182/blood.V110.11.5127.5127

Published: 2007

Journal Articles

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Elisabeth Wallhult, RN, John Whisnant, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Dileep Bhagwat, PhD, Kristoffer Hellstrand, MD, Bo I. Nilsson, MD, Mats L. Brune, MD

Blood (2007) 110 (11): 4381.

https://doi.org/10.1182/blood.V110.11.4381.4381

Published: 2007

Journal Articles

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Andrew C. Grigg, MD, Peter Shuttleworth, RN, John Reynolds, PhD, Jeff Szer, MD, Anthony P. Schwarer, MD, Andrew W. Roberts, MD, Ken F. Bradstock, MD, Chi-Hung Hui, MD, Richard Herrmann, MD, Peter Ebeling, MD

Blood (2004) 104 (11): 2253.

https://doi.org/10.1182/blood.V104.11.2253.2253

Published: 2004

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

NARROW

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Low Predictive Value of Functional Imaging with 18 FDG-PET or Gallium Scanning in Relapsed or Refractory Hodgkin Lymphoma Prior to Autologous Stem Cell Transplantation.

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Low Predictive Value of Functional Imaging with 18 FDG-PET or Gallium Scanning in Relapsed or Refractory Hodgkin Lymphoma Prior to Autologous Stem Cell Transplantation.

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only